NT
Intellia
NTLA·NASDAQCambridge MAFounded 2014750 employees
Mid CapbiotechPublicGenetic MedicineRare Disease
Platform: CRISPR In Vivo
Market Cap
$5B
All Drugs
3
Clinical Trials
7
Failed / Terminated
0
FDA Approved
1
Stock Price & Catalysts (NTLA)
Loading NTLA stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| NTL-2576 | NTL-2576 | NDA/BLA | 2 | SGLT2 | Pancreatic CaGastric Ca | ||
| Tiratapinarof | NTL-3850 | NDA/BLA | 1 | APOC3 | SLEPsA | ||
| Motanaritide | NTL-5036 | Approved | 4 | PD-1 | ThymomaPompe |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (6)